The UAE genetic testing market size was estimated at around USD 20.36 million in 2021 and it is projected to hit around USD 121.2 million by 2030, growing at a CAGR of 21.92% from 2022 to 2030
The incidence of cancer is significant in the UAE, and it is the country's third-largest cause of noncommunicable diseases (NCD)-related mortality. According to WHO 2020 report, the UAE has a cancer incidence and mortality of 4,807 and 1,896, respectively. The UAE became one of the fastest-growing economies in the world in the mid-twentieth century, with this expansion contributing to economic, sociodemographic, and lifestyle changes in its population as well as an epidemiological increase in NCD rates. The increasing cases of cancer has is also estimated to drive the market growth.
The technological advancements in diagnostic equipment have proven to be very useful in preventing, maintaining, and treating genetic diseases. It has also proven to be beneficial in prompt intervention for treating diseases when detected early in infancy through newborn screening. Aside from providing precise and reliable estimates of the prevalence of inherited diseases, molecular genetic testing is playing a vital role in the understanding of genetic disease's molecular pathology. This analysis is expected to improve prognosis and guide the development of customized molecular diagnostic methodologies against gene-related diseases.
In June 2021, the UAE announced a new first-of-its-kind institution focused on strengthening local genomic research as well as detecting and treating people with genetic abnormalities. This aims to assist in achieving the objective of enhancing health through cutting-edge academic research and the development of future researchers who will serve individuals and organizations in the UAE and around the region. These factors are expected to boost the market growth during the forecast period.
Genetic research & development in the country is playing a vital role in the advancements of personalized medicines. Due to the wide range of applications offered by genetic testing, the authorities are focusing on conducting innovative programs for citizens. For instance, in March 2018, the Dubai authority announced its ambitious plan to test the DNAs of all three million citizens. Increasing support by the government and favorable regulatory policies is anticipated to boost the demand for gene-related testing in the country.
Scope of The Report
|Market Size in 2021||USD 20.36 million|
|Revenue Forecast by 2030||USD 121.2 million|
|Growth rate from 2022 to 2030||CAGR of 21.92%
|Forecast Period||2022 to 2030|
|Segmentation||Technology, application, end-use, channel
|Companies Covered||Middle East Testing Services L.L.C; Molecular Biology & Genetics Laboratory; NSG; Freiburg Medical Laboratory Middle East; IVI MIDDLE EAST FERTILITY CLINIC; 23andMe, Inc.; Ancestry; CircleDNA; 24Genetics; MyDNA Life Australia Pty Ltd.|
The next-generation sequencing (NGS) segment held the highest revenue share of 46.52% in 2021 and is expected to witness the highest growth during the forecast period. In the global healthcare sector, NGS is steadily being integrated into clinical laboratory analysis, testing, and disease diagnoses. Increased genome mapping programs, expanded applications of NGS, increasing healthcare expenditure, and technological advancements in sequencing technology are all propelling the NGS market.
PCR-based testing is anticipated to witness significant growth during the forecast period till 2024. The growing incidences of target diseases and genetic abnormalities; ongoing technological innovations,the incorporation of robotics, and the development of miniaturized portable instruments, are some of the factors driving the growth of PCR technologies. Moreover, new test kits and techniques for disease diagnosis are being developed by companies.
For instance, in May 2020, Group 42 (G42), has collaborated with InterSystems to install InterSystems TrakCare Lab Enterprise (TCLE). TCLE will automatically report and conveniently submit PCR results to the Abu Dhabi Health Services Company (SEHA) and the Dubai Health Authority (DHA). These factors have contributed to the segment’s growth.
The ancestry & ethnicity application segment held the highest revenue share in 2021. Genetic ancestry screening, wherein genetic information is utilized to identify recent progenitors' geographic origins, has gained popularity. Furthermore, these tests reveal information about a person's ancestors and can help people connect with distant relatives, such as fourth or fifth cousins. In addition, the cost associated with these tests has reduced significantly and it has entered into the “direct to consumer” segment which is now referred to as recreational genetics.
Health and wellness segment is anticipated to witness significant growth during the forecast period. Predictive genetics testing and consumer/wellness genomics are in high demand due to the growing focus on healthy lifestyles and increased healthcare awareness campaigns. Hereditary testing can help forecast future disease risks and provide information and statistics about a child's genetic makeup. Furthermore, testing is useful for persons who have a family history of genetic disorders.
However, the high expense of genomic research equipment, as well as the complexity of predictive genetic testing and consumer/wellness genomics, are challenges that could limit market growth in the future.
The offline channel segment held the highest revenue share in 2021 owing to the integration of new molecular testing technologies, allowing the testing industry to expand at a rapid pace. As a result, a large number of private diagnostic testing laboratories are now offering a wide range of genetic testing services. A new trend in the supply of private molecular genetic testing services, such as saliva and buccal swab collection kits being offered for over-the-counter sales by pharmacies.
However, the online channel segment is anticipated to witness the fastest growth rate during the forecast period.Hereditary testing allows clinicians and patients to understand the risks of hereditary diseases. By testing at the early stage, individuals can make informed decisions that may minimize the risk of developing certain diseases. Smartphone applications, such as ShareDNA, provide relevant information about the genetic test results, and how to interpret those results, and reduces the information required of patients to use this service.
The hospital end-use segment held the highest market share in 2021 owing to the increasing prevalence of hospitalization of patients with genetic disorders in the country. The congenital malformation is the second major cause of mortality in the UAE. According to the Center for Arab Genomics Studies' database, there are 241 genetic abnormalities within the demographic; this figure is alarming given the country's small population size.
The rising prevalence of these disorders will be responsible for high patient visits to the hospitals, which would present the industry progression while impacting the market positively. In addition, increasing accessibility to modern technology in genetic testing and favorable reimbursement policies are contributing to fueling the demand for these testing in hospitals and clinics.
Furthermore, the diagnostic laboratories segment is expected to witness significant growth over the forecast period owing to increasing partnerships and collaboration of diagnostic laboratories with several companies operating in this market. For instance, Thermo Fisher Scientific enables laboratories to conduct hereditary research by providing technologies, such as quantitative PCR and next-generation sequencing. Similarly, in March 2022, GC Labs entered into collaboration with BioLab and Biotrust to deliver its testing services to laboratories while expanding its footprints in the region’s market. These factors contribute to the segment’s revenue growth in the coming years.
Non-Surgical Rhinoplasty Market (By Application: Indentations, Convex or concave nose, Asymmetry; By Type; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
U.S. Urgent Care Market (By Application: Acute Respiratory Infection, Injuries, Joint/Soft Tissue Issues; By Ownership) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Glaucoma Surgery Devices Market (By Product: Glaucoma Drainage Device, Laser System; By Surgery Method; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Transcatheter Aortic Valve Replacement Market (By Procedure: Transapical, Transfemoral, Transaortic)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Bioadhesive Wound Care Market (By Type: Fibrin Based Bioadhesive, PEG Based Bioadhesive, Cyanoacrylate Based Bioadhesive; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...